- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 17, Issue 2, 2011
Current Pharmaceutical Design - Volume 17, Issue 2, 2011
Volume 17, Issue 2, 2011
-
-
Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Authors: Shigeyuki Chaki and Hirohiko HikichiThe glutamatergic system is involved in a wide range of physiological processes in the brain, and its dysfunction plays an important role in the etiology and pathophysiology of psychiatric disorders, including schizophrenia. Among the glutamate receptors, metabotropic glutamate receptors (mGlu receptors) have emerged as attractive therapeutic targets for the development of novel interventions for psychiatric disorders. A Read More
-
-
-
Recent Advances in the Discovery of D-Amino Acid Oxidase Inhibitors and Their Therapeutic Utility in Schizophrenia
Authors: Dana V. Ferraris and Takashi TsukamotoD-Amino acid oxidase (DAAO) catalyzes the oxidative metabolism of D-amino acids including D-serine, a full agonist at the allosteric glycine binding site of the NMDA receptor. D-serine was reported to improve negative and cognitive symptoms of schizophrenia, symptoms poorly addressed by the standard D2 antagonist therapies. Therefore, inhibition of DAAO has gained substantial interest as an effective way to increase D-ser Read More
-
-
-
Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
Authors: Kenji Hashimoto and rThe hypofunction hypothesis of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a new therapeutic strategy for schizophrenia. The glycine modulatory site on NMDA receptor complex is the one of the most attractive therapeutic targets for schizoph Read More
-
-
-
α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia
Authors: Masatomo Ishikawa and Kenji HashimotoAccumulating evidence suggests that the α7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a role in the pathophysiology of schizophrenia. Deficits in auditory P50 evoked potential suppression in patients with schizophrenia are associated with decreased density of α7 nAChRs in the brain. Some agonists (e.g., DMXB-A and tropisetron) at α7 nAChRs can improve P50 deficits in patients with schizophrenia Read More
-
-
-
Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Authors: Norbert Muller, Aye-Mu Myint and Markus J. SchwarzThe disturbance of the dopaminergic neurotransmission is a key-feature in the neurobiology of schizophrenia. The interaction between the dopaminergic and the glutamatergic neurotransmission, however, attracted more notice to the glutamatergic system. Recent research focussed on factors influencing the glutamatergic neurotransmission. A pro-inflammatory immune state influences the glutamatergic neurotransmis Read More
-
-
-
Editorial [Hot topic:Novel Potential Therapeutic Approaches for Schizophrenia (Executive Guest Editor: Kenji Hashimoto)]
More LessSchizophrenia is a chronic, severe, and disabling brain disorder that affects about 1 percent of people worldwide. The manifestations of this disorder are positive symptoms (e.g., hallucinations, delusions, racing thoughts), negative symptoms (e.g., apathy, lack of emotion, poor or nonexistent social functioning), and cognitive deficits (e.g., poor executive functioning, trouble focusing or paying attention, problems wi Read More
-
-
-
PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Authors: Jan Kehler and Jacob NielsenDisturbances of the basal ganglia processes is heavily involved in schizophrenia. Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Biochemical and behavioral data indicate that PDE10A inhibition activates cAMP/PKA signalling Read More
-
-
-
Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
Authors: Silvia Paba, Roberto Frau, Sean C. Godar, Paola Devoto, Francesco Marrosu and Marco BortolatoThe enzyme steroid 5α-reductase (S5αR) catalyzes the conversion of Δ4-3-ketosteroid precursors - such as testosterone, progesterone and androstenedione - into their 5α-reduced metabolites. Although the current nomenclature assigns five enzymes to the S5αR family, only the types 1 and 2 appear to play an important role in steroidogenesis, mediating an overlapping set of reactions, albeit with distinct chemical chara Read More
-
-
-
Role of Polyunsaturated Fatty Acids and Fatty Acid Binding Protein in the Pathogenesis of Schizophrenia
Authors: Motoko Maekawa, Yuji Owada and Takeo YoshikawaSchizophrenia is a debilitating mental disorder that afflicts about 1% of the population worldwide. Despite intensive, multifaceted research, its exact etiology remains elusive. Epidemiological data shows that when pregnant mothers experienced malnutrition or famine (e.g. the Dutch Hunger Winter of 1994-1945 and the Chinese famine of 1959-1961), the risk of schizophrenia in their children increased by two fold. This fact co Read More
-
-
-
MicroRNAs: A Novel Therapeutic Target for Schizophrenia
Authors: Javier A. Bravo and Timothy G. DinanSchizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21-23 nucleotides in length that are not translated into proteins and regulate gene expression. The pres Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
